-
Signature
-
/s/ Christian Kuhlen, attorney-in-fact
-
Issuer symbol
-
ORIC
-
Transactions as of
-
23 Jun 2025
-
Transactions value $
-
-$351,384
-
Form type
-
4
-
Filing time
-
24 Jun 2025, 18:33:12 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Piscitelli Dominic |
Chief Financial Officer |
C/O ORIC PHARMACEUTICALS, INC., 240 E. GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO |
/s/ Christian Kuhlen, attorney-in-fact |
24 Jun 2025 |
0001695028 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
ORIC |
Common Stock |
Sale |
-$5,840 |
-584 |
-0.57% |
$10 |
101,233 |
23 Jun 2025 |
Direct |
F1 |
| transaction |
ORIC |
Common Stock |
Sale |
-$4,504 |
-450 |
-0.44% |
$10.01 |
100,783 |
23 Jun 2025 |
Direct |
F1 |
| transaction |
ORIC |
Common Stock |
Sale |
-$341,039 |
-32,466 |
-32% |
$10.5 |
68,317 |
24 Jun 2025 |
Direct |
F1, F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: